Abstract. Intrahepatic cholangiocarcinoma (ICC) is usually confirmed in advanced stage at the time of diagnosis or after surgical exploration, however, indication of surgical treatment is usually controversial for ICC in advanced stages. This retrospective study aims to evaluate clinical value of surgery for such tumors, in order to identify the appropriate patients who will benefit from surgery, and to evaluate the prognostic accuracy of the current staging system for advanced ICC. From January 2007 to December 2011, 387 consecutive surgically treated patients with ICC in AJCC-stage Ⅳ were evaluated. Survival was compared among different patients grouped by different elements of AJCC staging system. The prognostic importance of extent of lymph node (LN) metastasis relative to the AJCC N and M classification system was assessed. Our data showed that survival was much better for patients in AJCC-stage ⅣA group (median survival time, MST, 9.0 months) than in AJCC-stage ⅣB group (MST, 5.0 months) (P<0.001). While in AJCC-stage ⅣB group, survival for patients in AnyTN2-3M0 subgroup (MST, 9.0 months) was much better than in AnyTN0M1 subgroup (MST, 3.0 months); and better than in AnyTN2-3M1 subgroup (MST, 4.0 months) (P<0.001). Overall, R0 and R1 liver resection should be indicated for patients in AJCC-stage ⅣA group and AnyTN2-3M0 subgroup in AJCC-stage ⅣB group, as patients in these groups will benefit from surgery with relatively better survival. Staging of advanced ICC by N2-3 instead of M1 for extended LN metastasis classification is superior in comparison with the AJCC staging system.
Introduction
Intrahepatic cholangiocarcinoma (ICC), the second most common primary liver cancer after hepatocellular carcinoma (HCC), has been categorized as mass-forming type, periductular infiltrating type and intraductal growth type according to category of the gross type (1) . With a worldwide increase in the incidence rate in recent years (1) (2) (3) , however, ICC remains less understood and always has worse prognosis compared with HCC (3) (4) (5) , and practice guideline for treatment has not been universally accepted and thoroughly studied for ICC in advanced stage (6) . It has been generally believed that surgical resection is indicated for all potentially resectable ICC for the benefit of better survival (3, (6) (7) (8) (9) (10) and for the lack of other effective treatment options, but the prognosis remains dismal because the disease is usually advanced at the time of diagnosis or after surgery for quite a number of patients (6, 8, 11) . Up to 60% of ICC patients presented with disease in so advanced stage that made them not suitable for curative resection (3, (6) (7) (8) , as recurrence occurs frequently even after extended surgical resection (6, 8, 10) . Although recent studies suggest that curative/palliative resection can have beneficial impact on overall survival (OS) for some certain patients with advanced ICC (6, 8, 10, (12) (13) (14) , the range or extent of ICC tumor in advanced stage justifying aggressive surgery, however, has not reached a consensus for surgeons in different countries.
Current studies of surgical treatments for ICC usually enrolled patients with tumors in all stages according to the 7th edition American Joint Committee on Cancer (AJCC) staging Liver resection for intrahepatic cholangiocarcinoma in AJCC-stage Ⅳ: An evaluation of the survival benefit and prognostic accuracy of current AJCC staging system on N and M classification system (8, (15) (16) (17) (18) (19) . Owing to the relative paucity of this disease, most of the existing studies, however, usually involved small numbers of cases, spanned over a study period of decades, or were multicenter results with very small numbers per center, and in some studies patient inclusion was highly selective (concentrating on tumors in AJCC-stageⅠ-Ⅲ), leading to significant difference in OS among different studies and to controversies over surgical management of ICC especially in AJCC-stage Ⅳ. So, there is an increasing need for more comprehensive and more close data from large series to determine exact role of surgical treatment for ICC in AJCC-stage Ⅳ. In this retrospective study, we investigated surgical outcome, survival and the prognostic factors in a large series of consecutive patients with ICC in AJCC-stage Ⅳ at the time of diagnosis or after surgery (all of tumors were locally advanced but potentially resectable preoperatively) between 2007 and 2011 at a single institution, with the aim to evaluate safety and efficacy of surgical treatment, and the prognostic accuracy of AJCC staging system for patients with ICC in stage Ⅳ, and among which, to identify who would benefit from surgery.
Patients and methods
Patient recruiting and data collection. All consecutive patients with ICC who were admitted to the Eastern Hepato biliary Surgery Hospital, a high-volume center in China, for initial surgical treatment from January 2007 to December 2011, were retrospectively reviewed. Inclusion criteria included the following: no history of previous anticancer therapy; no history of other malignancies; no severe comorbidity that can affect survival or act as contra-indications for surgery; all the tumors were locally advanced but potentially resectable preoperatively, and were proven to be in stage Ⅳ according to AJCC staging system at the time of diagnosis or after surgery; all of the cases were histopathologically proven. Exclusion criteria were as follows: hilar or extrahepatic cholangiocarcinoma; mixed type of primary liver cancer; intraductal growth type or periductal infiltration type of ICC (because the case numbers of the other two pathological type were very small and bio-characteristics of the other two types were different from mass-forming type); definite distant metastasis before operation (localized/diffuse occult distant metastasis within abdomen were sometimes found during surgical exploration, and some of such patients obtained resection); and incomplete clinical or survival data (Fig. 1) . Demographic data for all patients, including age, gender, symptoms, underlying liver diseases, image findings, and laboratory test were collected. This study was approved by the local Ethics Committee.
Preoperative workup and surgery. Routine preoperative workup consisted of, but was not limited to, ultrasound scanning, three-phase computed tomography (CT) or magnetic resonance imaging (MRI) of the liver, endoscopic examination and laboratory tests. Patients underwent surgical exploration if preoperative image indicated a potentially resectable ICC and there were no general contra-indications for surgery. However, radiographic studies had a limited ability to determine respectability. Most of the liver resections were carried out under vascular control, and both anatomical and non-anatomic hepatectomy were performed depending on the size and location of tumor. The surgical radicality and margins were evaluated and examined for the presence of residual tumor which was described by the following classification: R0, no residual tumor and resection margin was >0 mm; R1, microscopic residual tumor or resection margin was nil; R2, macroscopic residual tumor (4, 20, 21) or macroscopic unresectable LN metastasis. All of the patients enrolled in this study underwent resection of lesions with curative (R0) or relatively curative (R1) intention, even when occult distant metastasis within abdomen such as localized peritoneal/diaphragm seeding, and localized omentum metastasis were found. Palliative resection (R2) intention was never suggested to apply before operation, neither was exploratory laparotomy with biopsy, except when the findings of intraoperative exploration were beyond preoperative evaluation of ICC and R0/R1 resection could not be obtained, such as disseminated intrahepatic tumor spread, disseminated peritoneal/diaphragm seeding, diffuse/unresectable fixed LN metastasis with vascular invasion were found beyond preoperative evaluation of ICC, depending on intraoperative assessment of value and safety of surgery. In patients with suspected LN metastasis (preoperative and during operation), liver resection together with lymph node dissection (LND) was performed when possible (regional and extended LND but seldom into the para-aortic regions); liver resection with only lymph node biopsy (LNB) was performed, when diffuse/unresectable fixed LN metastasis with vascular invasion was encountered and the intrahepatic tumor was localized at the same time; LNB was also performed when the primary tumors were unresectable to help to confirm metastasis; in other patients with intrahepatic tumor curatively resected and with no evidence of macroscopic LN enlargement, preventive skeletonization of the hepatoduodenal ligament was performed, with the aim to confirm the stage.
Pathological evaluation. Diagnosis ICC was based on macroscopic examination, H&E staining, and immunohistochemical study of the resected or biopsy specimens. Pathological characteristics, including tumor size and number, capsule formation, LN metastasis, vascular invasion, perineural invasion and tumor cell differentiation, were collected for all the patients. Each tumor was staged according to AJCC staging system for ICC (19, 22) , and classified by the category of the gross type of ICC by the Liver Cancer Study Group of Japan (23) . Based on the factors of LN metastasis and distant metastasis, we divided patients with tumors in stage AJCC-stage ⅣB into three subgroups according to our new staging system: patients with tumors (AnyTN2-3M0), patients with tumors (AnyTN0-1M1), and patients with tumors (AnyTN2-3M1). Differences of our new staging system and AJCC 7th staging system are listed in Table Ⅰ .
Follow-up. All patients were followed up by ultrasound scan and tests for liver function and the levels of α-fetal protein (AFP), carbohydrate antigen 19-9 (CA19-9) and carcinoembryonic antigen (CEA) at an interval of 1 month for the first year, 1-2 months for the second year, and every 3 months the year after, if there was no recurrence. When tumor recurrences were suspected, CT or MRI scan would be performed to confirm the diagnosis. Treatments of recurrent disease included surgery, transarterial chemoembolization (TACE), radiotherapy, and supportive therapy. Patients were followed for survival until death or the study deadline date of 30 September, 2014.
Statistical analysis. Continuous variables were presented as the mean ± SD. Independence tests were performed using unpaired t-test for continuous variables and Chi-square or Wilcoxon test for categorical variables. OS rates were calculated with the Kaplan-Meier method. The possible prognostic factors were analyzed by the univariate analysis and evaluated using the Kaplan-Meier method and compared by the log-rank test. The multivariate analysis was performed using the Cox proportional hazards model to identify the independent prognostic factors. Table Ⅱ , and with more details in Table Ⅲ .
Surgical results. Of the 387 ICC patients, 343 received liver resection, with an overall resectability rate of 88.7%. R0, R1 and R2 resections were obtained in 22 (5.7%), 133 (34.3%) and 188 (48.6%) patients, respectively, and the remaining 44 (11.4%) patients had only laparotomy and biopsy (tumor and/or LN) because of extensive intrahepatic metastases or peritoneal seeding. LN metastasis occurred in 375 (96.9%) patients, among which, 154 patients obtained complete LND, including LN around the hepatoduodenal ligament, the left gastric artery, the common hepatic artery, the celiac trunk, and even the para-aortic regions, in addition to liver resection. In other 186 patients with LN metastasis, liver resection with only LNB was performed, which were the mainstay of R2 resection in this study, with residual tumor in the liver as the second most common cause. The remaining 35 patients with LN metastasis were among those who had only laparotomy exploration and biopsy. In 12 patients without LN metastasis, 3 patients obtained tumor resection with preventive skeletonization of the hepatoduodenal ligament, the other 9 patients had only laparotomy exploration and biopsy of tumor. Operative death, which was defined as death within 30 days of surgery or death that occurred during same admission period (24) , occurred in three cases with an operative mortality of 0.8%. Of the three operative deaths, two cases occurred in ⅣA group, while the other one occurred in AnyTN2-3M1 group, and all of these cases occurred in R2 resection group. According to the Clavien-Dindo classification (24), postoperative complications developed in 14 (3.6%) cases, with 10/298 (3.4%) in ⅣA group, 2/23 (8.7%) in AnyTN2-3M0 group, 1/12 (8.3%) cases in AnyTN0-1M1 group, and 1/54 (1.9%) in AnyTN2-3M1 group. Of the cases with postoperative complications, 5/133 cases (3.8%) occurred in R1 resection group, 9/188 cases (4.8%) occurred in R2 resection group, and there were no cases in R0 resection group and laparotomy group. Except 3 patients who died of hepatic failure or multiple organ failure, all the patients successfully recovered from the complications.
Adjuvant therapy. Adjuvant chemotherapy was not recommended for patients with R0 resection, while 42.9% (57) of patients with R1 resection received transarterial chemoembolization (TACE) 4 weeks after surgery and 31.5% (73) of the patients with unresectable disease or with R2 resection received adjuvant chemo/radiotherapy. The most common chemotherapy regimen was 5-fluorouracil (FU) combined with cisplatin and gemcitabine, and three dimensional conformal radiotherapy was the standard radiation therapy that was used mainly for residual positive LN. The data are provided as n (%) except for age and tumor size which are expressed as mean ± SD. a In cases of multiple tumors, the diameter of the largest nodule represents the size of the tumor.
Survival

Status of residual tumor after surgery and its influence on survival.
In patients with ICC in AJCC-stage Ⅳ, those who obtained R0 resection, the 1-, 3-and 5-year OS rates were 68.2, 13.6 and 0%, respectively, with an MST of 14.0 months; while for those who obtained R1 resection, the 1-, 3-and 5-year OS rates were 49.6, 11.9 and 3.3%, respectively, with an MST of 12.0 months (P<0.001, Fig. 4) . The 1-, 3-and 5-year OS rates were 20.7, 3.7 and 1.1%, respectively, in patients with R2 resection (MST, 6.0 months), much better than 2.3, 0.0 and 0.0% in patients with only exploratory laparotomy and biopsy (MST, 4.0 months) (P<0.001, Fig. 4 ).
In patients with ICC in AJCC-stage ⅣA, those who obtained R0 resection, the 1-, 3-and 5-year OS rates were 68.2, 13.6 and 0%, respectively, with an MST of 14.0 months; while for those who obtained R1 resection, the 1-, 3-and 5-year OS rates were 49.6, 11.5 and 3.1%, respectively, with an MST of 12.0 months (P<0.001, Fig. 5 ). The 1-, 3-and 5-year OS rates were 22.0, 4.3 and 1.4%, respectively, in patients with R2 resection (MST, 6.0 months), much better than 7.1, 0.0 and 0.0% in patients with only exploratory laparotomy and biopsy (MST, 7.0 months) (P<0.001, Fig. 5 ).
In patients with ICC in AJCC-stage ⅣB, nobody obtained R0 resection in this group, and the 1-, 3-and 5-year OS rates were 50.0, 16.7 and 0.0%, respectively, for those who obtained R1 resection (MST, 11.0 months). The 1-, 3-and 5-year The data are provided as n (%) except for age and tumor size which are expressed as mean ± SD. 
Discussion
To the best of our knowledge, this is the largest study involving surgically treated patients with ICC in AJCC-stage Ⅳ, so the results of our study would reflect the current profile of surgical treatment of such patients. ICC has been proved to be a highly malignant neoplasm, and extraordinary attention has been paid on the factors that influence the prognosis of ICC following surgical resection in our previous study (25) and other reports (4, 12, (15) (16) (17) (18) 21, (26) (27) (28) (29) (30) (31) , but these studies usually related to potential resectable ICC in all stages, and never focused only on ICC in AJCC-stage Ⅳ. We would not operate on patients with M1 disease definitely diagnosed before operation, however, occult distant metastasis within abdomen was sometimes found during surgical explora- tion, and some of such patients obtained resection, thus, it turned out that patients with M1 disease were enrolled in this study. Although patients with ICC in stage Ⅳ would rarely undergo a resection in the Western world, our study demonstrated that surgery is still valuable for at least part of these patients, because natural history without any treatment for ICCs in advanced stage was even worse with an MST of only 3.0 months (203 cases) (32) , and similiar patients with supportive therapy alone had a MST of 4.9 months (12 cases) (33) . An MST of 12.9 months was reported for advanced ICC by palliative chemoradiotherapy (33) , which seemed superior than our result (MST, 8.1 months) , however, the number of reported patients was small (28 cases) and the evidence was weak. This study demonstrated that the prognosis of ICC in AJCC-stage Ⅳ was unfavorable even after surgical management, with an MST of 8.1 months, because compared with the former studies (4, 6, 8, 11, 12, (15) (16) (17) (18) 25, 27) , ICC in this series was more frequently associated with lymph node involvement, multiple tumors, peritoneal dissemination, and low R0 resection rate. However, such patients could definitely benefit from surgery when R0 or R1 resection was available.
Generally speaking, resection was attempted for ICC whenever possible (3,6-11), leading to varied surgical margin statuses, such as R0, R1, R2 resection, and exploratory laparotomy. Our study, like some reported studies (6, 12, 21, 34) , showed that the resection margin status was an independent variable that influenced the prognosis of ICC following surgery. In this series (Fig. 3) , surgery was again proven valuable for that R0 resection (MST, 14.0 months) and R1 resection (MST, 12.0 months) provided better survival than R2 resection (MST, 6.0 months) and non-resective biopsy (MST, 4.0 months). However, R0 resection is not feasible in a considerable proportion especially for ICC cases with tumor in stage Ⅳ, and in this study, only ~5.7% patients obtained R0 resection, much lower than that of our previous study (25) and the literatures (ranging from 19.8 to 80.0%) (3) (4) (5) 12, (15) (16) (17) 21, (26) (27) (28) (29) (30) (31) 35, 36) , owing to different inclusion criteria. However, in present series, the overall resectability rate was 88.7%, which was, to our knowledge, much higher than the reported series including patients with tumors even in earlier stage (ranging from 18 to 77%) (7, 8, 10, 15, 17, 23, 30) . All these data might account for low R0 resection rate in this study, which was suggested to be responsible for poor prognosis of ICC in stage Ⅳ following surgery, and R0 resection is definitely recommended and valuable when possible for such patients.
In the present study, R1 resection occurred in 34.4% of the whole cohort, owing to disadvantageous factors such as large tumors (median size, 7.0 cm), multiple tumors (51.2%), centrally located tumors, and incomplete tumor capsule with ill-defined borders. Although in this study, R1 resection had significant unfavorable influence on patient survival when compared to R0 resection (MST: 14 months vs 12 months), and although there has been controversy about the effect of R1 resection on patient survival in the literature (4, 6, 12, 16, 20, 21, 28, 34) , patients obtained R1 resection survived significantly longer than those with R2 resection or laparotomy (Figs. 4-6) . Therefore, R1 resection is recommended when R0 resection cannot be obtained, not only for its relative curativity but also for ubiquitous unfavorable pathological features of ICC in stage Ⅳ.
Previously it was suggested that all types of cancer-directed surgery including palliative surgery may offer a survival advantage over no surgery (32, 37) . Controversy exists over the justification of R2 resection. Some authors reported that R2 resection did not provide any survival benefit but only bore the risks of major hepatic surgery (6, 34, 38) , whereas others believed that some patients could benefit from R2 resection (12, 13, 36) . In current series, more than half of the patients with LN metastasis obtained only liver resection with residue positive nodal, which was the most common cause of R2. Although patients obtained R2 resection survived a little longer than those undergoing only exploratory laparotomy (MST, 6.0/4.0 months) (Figs. 4-6) , it showed no significant advantage over those with chemoradiotherapy, or supportive therapy alone, or without any treatment (32, 33) . Thus, during surgical exploration, R2 resection is not recommended.
Up till now, routine lymphadenectomy did not receive unified agreement during surgery especially for ICC in stage Ⅳ, not only considering the stage of tumor and the extent of LN metastasis, but also as the debate existed both in the literatures (9, 11, 29, (39) (40) (41) (42) and within the surgeons of our hospital for whether such patients could necessarily benefit from standardized LN dissection for prolonged survival. In current series, complete LND was achieved in 154 patients with relatively localized tumors and better range of LN metastasis, while 221 patients underwent LNB because of either diffuse/unresectable fixed LN metastasis or unresectable tumor. Although observations in hilar cholangiocarcinoma (43) and ICC (8) revealed that para-aortic lymphadenectomy may result in improved long-term survival in macroscopically negative but microscopically positive para-aortic LN, extended LN dissection was obtained in celiac trunk, retropancreatic and even into para-aortic regions only in a small number of patients (R1 resection in ⅣB) give consideration to the unsatisfactory surgical radicality of primary liver tumor itself. In this study, results showed that patients with liver resection with LN dissection survived significantly longer than those with LN biopsy for patients without distant metastasis (stage ⅣA + AnyTN2-3M0), suggesting that LN dissection should be performed when suitable for the benefit of better survival.
Different from former studies (9, 11, 25, 29, (39) (40) (41) (42) , LN metastasis, one of the key elements constituting AJCC staging system (19, 22) , was proved to be a favorable prognostic factor for ICC patients only in this series. In fact, there were 375 (96.9%) patients with LN metastasis in this cohort, with 298 (100%) patients in ⅣA group and 77 (86.5%) patients in ⅣB group, leading to more advanced stage and worse prognosis for tumors of patients without LN metastasis. On the other hand, in ⅣB group of this series, patients with extended LN metastasis (N2-3) may not have significantly poorer survival than those with regional (N1) LN metastasis or without LN metastasis (Fig. 2) , was inconsistent with current AJCC staging system (19, 22) , where extended LN metastasis (N2-3) was emphasized as an extremely poor prognostic factor in such a strong way that it was classified as distant metastasis (M1). In this study, we found that, patients in group ⅣA and/or subgroup AnyTN2-3M0 had better survival than in subgroup AnyTN0-1M1 and/or AnyTN2-3M1, while survival was better in patients in subgroup AnyTN2-3M1 than subgroup AnyTN0-1M1. Survival was similar between patients in group ⅣA and subgroup AnyTN2-3M0. These results all suggested that M1 was a stronger poor prognostic factor for ICC than extended LN metastasis (N2-3), which was different from opinions of current AJCC staging system (19, 22) . Moreover, the above data of our study indicated that, using N2-3 instead of M1 to classify extended LN metastasis with involvement of the celiac, periaortic, or caval lymph nodes was more accurate not only in staging ICC but also in estimating survival of patients with ICC A prognostic and staging system of ICC should be developed based on the outcomes of all the cases for providing guideline on the appropriate of surgery as treatment option. An evaluation of the prognostic accuracy of the 7th edition AJCC staging system is missing for ICC in AJCC-stage Ⅳ as yet. Specifically, the N and M classification of current AJCC staging system for ICC seemed to be prognostically inaccurate. We use N2-3 instead of M1 for extended LN metastasis classification to stage advanced ICC, thus ICC in stage ⅣB (AJCC 7th) were divided into three subgroups: AnyTN2-3M0, AnyTN0-1M1, and AnyTN2-3M1. The 1-and 3-year OS for patients in group AnyTN2-3M0 were different but close to group ⅣA; while the 1-and 5-year OS for patients in group AnyTN0M1 were different but close to group AnyTN2-3M1. Thus, AnyTN2-3M0 should be included in stage ⅣA, while AnyTN0-1M1 and AnyTN2-3M1 should be included in stage ⅣB (Table Ⅰ) . This classification was more precise for prediction of outcome in patients with advanced ICC.
However, the current study has several limitations. It is a retrospective single institution study over a 5-year period, during which significant changes in surgical technic, adjuvant therapies and standpoints of surgeons occurred. Our study repre sents more recent data compared with the former studies in the literature. In addition, there is likely a selection bias; patients with unreconstructable vasculature, significant preoperative comorbidity, and extremely advanced tumor biology (as demonstrated by rapid tumor progression or metastases) were likely not offered resection and thus not included in this study.
In conclusion, liver resections, including R0 and R1 resections, could provide survival benefit to the patients with ICC in stage Ⅳ. Patients with ICC in stage ⅣA and AnyTN2-3M0 are candidates for surgery especially when R0 or R1 resections could be obtained, not only for safety, but also for possibility of long-term survival in these patients. R2 resection should be avoided for patients with ICC in both stage ⅣA and ⅣB, for whom, surgery should be attempted if there are no sign of M1 before operation, and should be ceased when any evidence of M1 was found during surgical exploration. The current AJCC staging system on N and M classification for ICC does not accurately stratify patients with regard to prognosis. Staging of advanced ICC by N2-3 instead of M1 for extended LN metastasis classification is superior in comparison with current AJCC staging system.
